You are here

  • Home
  • Archive
  • Volume 6, Issue 1
  • Glucagon-like peptide-1 receptor agonists are not associated with retinal adverse events in the FDA Adverse Event Reporting System

Article metrics

Article menu

Download PDFPDF

XML
Pathophysiology/Complications
Glucagon-like peptide-1 receptor agonists are not associated with retinal adverse events in the FDA Adverse Event Reporting System

 

Online download statistics by month:

Online download statistics by month: January 2018 to March 2024

AbstractFullPdf
Jan 201811111125
Feb 2018349343886
Mar 201820620788
Apr 201810310251
May 201810811519
Jun 201817517749
Jul 2018716828
Aug 2018114111156
Sep 201810910672
Oct 201812312154
Nov 201811611644
Dec 201823323156
Jan 201914614547
Feb 201914314153
Mar 201910610473
Apr 2019434317
May 2019575432
Jun 2019414131
Jul 2019494941
Aug 2019403820
Sep 2019363625
Oct 2019474530
Nov 2019222235
Dec 2019383824
Jan 2020232314
Feb 2020414036
Mar 2020383819
Apr 202031325
May 2020353516
Jun 2020242415
Jul 202022217
Aug 2020302812
Sep 2020564416
Oct 2020554844
Nov 2020665716
Dec 2020666226
Jan 2021585519
Feb 2021676520
Mar 2021857822
Apr 2021747212
May 2021817920
Jun 2021424013
Jul 2021464518
Aug 2021403921
Sep 2021464320
Oct 2021484426
Nov 2021403728
Dec 2021454414
Jan 2022333614
Feb 2022353626
Mar 2022505117
Apr 2022333413
May 2022484821
Jun 2022272611
Jul 2022484414
Aug 2022474611
Sep 2022313119
Oct 202245417
Nov 2022333112
Dec 2022272811
Jan 2023464110
Feb 2023454414
Mar 2023495219
Apr 2023272616
May 2023343114
Jul 2023373646
Aug 2023616414
Sep 202343457
Oct 2023504313
Nov 2023585514
Dec 2023464412
Jan 2024393914
Feb 2024403921
Mar 2024615923
Total483847272828